Overture Life Enters UAE Market Through Emitac Partnership to Expand Automated IVF Across the Gulf Advancing Reproductive Automation in the Region
Overture Life, a leading developer of automated in vitro fertilization (IVF) technologies and the first company to report live births resulting from both robotic fertilization and robotic egg freezing, has announced a strategic partnership with Emitac Healthcare Solutions. Emitac is a prominent distributor of advanced medical and laboratory technologies operating across the United Arab Emirates (UAE), Saudi Arabia, Oman, and pan-African markets. Through this collaboration, the two organizations aim to introduce Overture’s DaVitri automated IVF laboratory platform to fertility clinics throughout the UAE, marking a significant milestone in the region’s evolving reproductive healthcare landscape.
The UAE launch represents a continuation of Overture Life’s rapid international expansion strategy. Following recent market entries in Brazil and India, the company is now establishing its first operational presence in the Middle East. This move reflects the growing global demand for automation in reproductive medicine, particularly in high-volume fertility markets where clinics are increasingly seeking scalable, standardized, and reproducible laboratory solutions. The expansion also underscores a broader shift in embryology toward automation-driven systems designed to reduce human variability and improve consistency in critical IVF procedures.
At the center of this rollout is DaVitri, Overture Life’s automated vitrification platform. Vitrification, the ultra-rapid freezing of eggs and embryos, is a highly sensitive procedure in IVF laboratories and traditionally relies heavily on manual skill and operator experience. DaVitri replaces much of this variability with a regulated, microfluidic automation system designed to standardize the process. By controlling timing, temperature, and fluid dynamics with precision engineering, the platform minimizes inconsistencies that can impact egg survival rates and downstream embryo development.
The DaVitri system has already achieved regulatory clearance from the UAE Ministry of Health and Prevention (MOHAP). In parallel, regulatory submissions and approval pathways are underway in Saudi Arabia and Oman, signaling broader regional adoption in the near future. With existing clearances across the United States, Europe, South America, and now the UAE, DaVitri has become one of the most widely authorized automated IVF platforms globally. This regulatory footprint reflects a deliberate commercialization strategy focused on regions with high IVF demand, advanced healthcare infrastructure, and growing investment in reproductive technologies.
“Last year, Overture was preparing for a global launch. Today, we are operating across four continents, and the pace reflects what the market is telling us, which is that automation is the standard that the leading clinics are adopting now,” said Hans Gangeskar, Chief Executive Officer of Overture Life. “The UAE is a strategic anchor for the Gulf. Emitac Healthcare Solutions brings the local accountability, training capability, and service infrastructure that make adoption sustainable, and together we are giving UAE clinics a fully supported path to making robotic embryology the regional standard.”
His remarks highlight the company’s broader thesis that IVF laboratory automation is transitioning from an emerging innovation to an operational necessity in leading fertility centers. According to Overture Life, clinics are increasingly seeking technologies that not only improve outcomes but also reduce procedural variability between operators, laboratories, and geographies. In this context, automation is positioned not as a replacement for embryologists, but as a system-level enhancement that standardizes complex workflows while allowing clinical teams to focus on decision-making and patient care.
The UAE has emerged as one of the most dynamic fertility treatment destinations in the Middle East. Its clinics attract patients not only from within the Gulf Cooperation Council (GCC) countries but also from North Africa, South Asia, and increasingly Europe. This international patient inflow has placed pressure on fertility centers to deliver consistent, high-quality outcomes at scale. As IVF cycles become more complex and patient expectations rise, variability in laboratory procedures—particularly in egg freezing and warming—remains a key challenge affecting success rates and repeat treatment cycles.
Clinics in the region also face growing commercial pressures. Fertility care is both clinically intensive and resource-heavy, requiring highly trained embryologists, specialized equipment, and tightly controlled laboratory environments. Even minor inconsistencies in technique can significantly influence outcomes, which in turn affects clinic reputation, patient retention, and international competitiveness. In this environment, technologies that reduce variability and increase reproducibility are gaining strategic importance.
For Emitac Healthcare Solutions, the partnership represents an opportunity to introduce a clinically validated platform that has already been deployed across multiple global regions. Emitac’s role extends beyond distribution; it includes providing clinical training, technical support, and ongoing service infrastructure required for successful adoption in day-to-day laboratory settings. The company’s established presence across the Middle East and Africa positions it as a critical enabler for scaling advanced fertility technologies in the region.
“DaVitri arrives in the UAE already proven across three continents, cleared by leading regulators, and operating in clinics that are setting global benchmarks for reproducible IVF outcomes,” said Mohd Kenanah, Chief Executive Officer of Emitac Healthcare Solutions. “Our role is to ensure UAE clinics can adopt this platform with the same confidence and clinical rigor that has driven its rapid international adoption, and to position the country as the Gulf region’s leader in the next generation of fertility care.”
His comments reflect the UAE’s ambition to strengthen its position as a regional hub for advanced medical technologies. In recent years, the country has invested heavily in healthcare innovation, including precision medicine, digital health infrastructure, and specialized clinical services. Fertility care has become a particularly competitive sector, with both public and private providers seeking to differentiate through technology adoption and improved patient outcomes.
Clinical evaluations of DaVitri have indicated improvements in post-thaw embryo development compared with traditional manual vitrification methods. In addition to performance gains, the platform is designed to significantly increase laboratory throughput without requiring proportional increases in staffing levels. This scalability is particularly relevant for high-volume fertility centers, where demand often exceeds available embryology capacity.
Another key advantage of the DaVitri system is its ability to reduce infrastructure costs associated with establishing or expanding IVF laboratories. Traditional embryology labs require substantial investment in equipment, controlled environments, and highly specialized personnel. By automating key processes, DaVitri reduces the need for extensive manual intervention and lowers the barrier to entry for clinics aiming to expand their fertility service offerings. This enables both large hospital networks and smaller satellite clinics to access advanced reproductive technologies that were previously limited to high-resource settings.
The broader implication of this shift is the democratization of advanced IVF capabilities. As automation reduces both cost and complexity, more clinics across diverse geographies can offer standardized fertility services. This trend has the potential to reshape global reproductive healthcare by expanding access while maintaining or improving clinical quality.
The UAE launch also serves as a foundation for further expansion across the Gulf Cooperation Council and the wider Middle East. Overture Life has indicated that additional market entries are planned over the coming year as part of its global commercialization roadmap. These expansions will likely focus on regions with strong fertility treatment demand and governments that are actively investing in healthcare modernization.
As automated embryology continues to gain traction globally, partnerships such as the one between Overture Life and Emitac Healthcare Solutions highlight the convergence of technology innovation, regulatory alignment, and regional healthcare strategy. Together, they signal a shift toward a new era in reproductive medicine—one where precision automation plays a central role in improving consistency, scaling access, and redefining standards of care in IVF laboratories worldwide.
Source link: https://www.businesswire.com/
